Journal
CURRENT MOLECULAR MEDICINE
Volume 23, Issue 7, Pages 606-629Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566524022666220509122505
Keywords
FENDRR; lncRNAs; cancer; regulatory mechanism; biomarker; RNAs
Categories
Ask authors/readers for more resources
Long noncoding RNAs (lncRNAs) have been recognized as vital regulators of tumor establishment and are frequently dysregulated in various cancers. FENDRR (fetal-lethal noncoding developmental regulatory RNA) serves as a key lncRNA in multiple malignancies, playing a crucial role in organ development and influencing signaling pathways in different cancers. Moreover, FENDRR has been found to modulate the development and progression of several cancers, as well as epigenetic regulation of target genes involved in tumor immunity. This review highlights the biological functions and molecular mechanisms of FENDRR in different cancers, emphasizing its potential as a cancer biomarker and a potential therapeutic target.
Long noncoding RNAs (lncRNAs) are prominent as crucial regulators of tumor establishment and are repeatedly dysregulated in multiple cancers. Therefore, lncRNAs have been identified to play an essential function in carcinogenesis and progression of cancer at genetic and epigenetic levels. FENDRR (fetal-lethal noncoding developmental regulatory RNA) as a LncRNA is a hallmark of various malignancies. FENDRR is crucial for multiple organs' development, such as the lung and heart. The effects of FENDRR under signaling pathways in different cancers have been identified. In addition, it has been verified that FENDRR can affect the development and progression of various cancers. In addition, FENDRR expression has been associated with epigenetic regulation of target genes participating in tumor immunity. Furthermore, FENDRR downregulation was observed in various types of cancers, including colorectal cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma, liver cancer, gallbladder cancer, lung cancer, breast cancer, endometrial cancer, prostate cancer, chronic myeloid leukemia, osteosarcoma, and cutaneous malignant melanoma cells. Here, we review the biological functions and molecular mechanisms of FENDRR in several cancers, and we will discuss its potential as a cancer biomarker and as a probable option for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available